Literature DB >> 2718781

Parathyroid function in Paget's disease of bone.

E S Siris1, T P Clemens, D McMahon, A Gordon, T P Jacobs, R E Canfield.   

Abstract

In order to determine the prevalence of secondary hyperparathyroidism in patients with Paget's disease of bone, we measured serum parathyroid hormone levels (N-terminal assay) in 39 patients with a wide range of pagetic activity. All patients had normal serum calcium levels. A total of 30 patients were either untreated or had received no treatment for 6 months or longer when studied; the other 9 were receiving either salmon calcitonin (3) or EHDP (6). The results showed that in 7 of the 39 patients (18%) parathyroid hormone levels were increased above normal. These were among the most severely affected cases, as manifested by the degree of elevation of three pagetic biochemical indices: serum alkaline phosphatase, plasma bone Gla protein, and 24 h urinary hydroxyproline-creatinine ratios. Levels of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 were normal. We examined the relationships between parathyroid hormone and each of the three pagetic indices as well as serum calcium for the entire group of 39 patients. Parathyroid hormone values did not correlate with serum calcium measurements (r = -0.241, p = NS) but did correlate significantly with serum alkaline phosphatase (r = 0.496, p less than 0.001), plasma bone Gla protein (r = 0.537, p less than 0.001), and urinary hydroxyproline (r = 0.450, p less than 0.011). We conclude that relative or absolute increases in parathyroid hormone may occur in moderately active Paget's disease, possibly in the setting of greater calcium demands during periods of increased pagetic new bone formation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2718781     DOI: 10.1002/jbmr.5650040111

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

Review 1.  Paget's disease of bone: diagnosis and treatment update.

Authors:  M Noor; D Shoback
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

Review 2.  Paget's disease of bone: a disease of the osteoclast.

Authors:  S V Reddy; N Kurihara; C Menaa; G D Roodman
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

Review 3.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 4.  Paget's disease of bone.

Authors:  C G Ooi; W D Fraser
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

5.  Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease.

Authors:  A Kukita; C Chenu; L M McManus; G R Mundy; G D Roodman
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

6.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

7.  A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.

Authors:  Yuko Hiruma; Noriyoshi Kurihara; Mark A Subler; Hua Zhou; Christina S Boykin; Heju Zhang; Seiichi Ishizuka; David W Dempster; G David Roodman; Jolene J Windle
Journal:  Hum Mol Genet       Date:  2008-09-02       Impact factor: 6.150

8.  Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.

Authors:  J-P Devogelaer; P Bergmann; J-J Body; Y Boutsen; S Goemaere; J-M Kaufman; J-Y Reginster; S Rozenberg; S Boonen
Journal:  Osteoporos Int       Date:  2008-05-27       Impact factor: 4.507

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.